Ready to Revolutionise Your Clinical Trials?
Allow us to show you what we can do.
If you're ready to make your cancer trials more efficient and cost-effective, get in touch with us today. We’d love to show you how Biomine can help you predict treatment responders and streamline your trials.
Why Partner With Biomine
At Biomine, we combine deep expertise in microbiome science with a track record of innovation.
As a Techstars-backed startup, our team is dedicated to transforming clinical trials with data-driven insights.
We’re not just another biotech company—we’re your partner in making cancer trials more predictable and efficient.
Let’s revolutionise the future of immunotherapy trials together.
01
Start Faster, Finish Sooner
Predict responders before enrolment — reduce recruitment time, hit endpoints sooner, and accelerate timelines.
02
Cut Trial Costs by Up to 30%
Avoid enrolling non-responders. Fewer patients needed, fewer failed endpoints, less waste.
03
Increase Trial Success Rates
By selecting the right patients, you improve signal clarity and reduce trial failure risk.
04
Get Actionable Insights, Fast
No waiting for post-hoc biomarker discovery. We deliver predictive stratification before your trial begins.
05
Works with Your Workflow
Biomine integrates with existing trial ops — no major protocol changes, no extra hassle. Just smarter screening.
Biomine’s Predictive Microbiome Platform
Prediction-First Trial Design
We use microbiome signatures to predict which patients are most likely to respond to immunotherapies — before the trial even begins. This enables more targeted recruitment and smarter trial design.
Real-Time Patient Stratification
Our platform helps trial sponsors select the right patients at the right time. This reduces trial noise, improves endpoint clarity, and accelerates timelines — without changing the drug.
Simple Integration:
How It Works
Collecting Microbiome Samples
We gather simple, non-invasive gut microbiome samples from trial participants.
Running Predictive Analytics
Our platform analyzes these samples to predict which participants are most likely to respond to the treatment.
.png)
Delivering Actionable Insights
We provide CROs and trial sponsors with clear, actionable data so they can run more efficient and cost-effective trials.
Oncology trials have bloated costs and extended timeframes
The Challenge in Cancer Immunotherapy Trials
Today, cancer immunotherapy is a game-changer for some patients, but only a minority of patients actually respond to these treatments, leaving trials with high costs and a lot of uncertainty. Our challenge is that we can't reliably predict who will benefit before a trial starts. That means a huge portion of patients and resources are used on treatments that might not work for them. That's the problem we're here to solve.
The Case for Predictive Screening in Cancer Trials
$1.6B
Cost of Failure
20-40%
Immunotherapy Response Rate
6.5yr ave
Average Cancer Trial Duration
2.7x higher
Biomarker-Driven Trial Success
